Pipeline

Pipeline

PixCell is developing additional assays for the HemoScreen™.
These assays are based on a patented technology: Imaging Flow Immuno-Assay (IFIA)

Early Sepsis Diagnosis

Sepsis is the body’s overwhelming and life-threatening response to infection that can lead to tissue damage, organ failure, and death. Early diagnosis, and timely and appropriate use of antibiotics is crucial, with the potential to save millions of lives every year.

PixCell is developing a novel assay for timely and accurate diagnosis of sepsis with a unique combination of immune response and cellular level markers.

36 million

mortality rate

3rd ranking

cause of death

25-30%

mortality rate

1.5% increase

every year

1 hour delay

in antibiotics
increases mortality by 8%

Early Cancer Diagnosis

Abnormal blood cells which are prematurely released from the bone marrow into the blood stream may indicate blood cancers or other severe disorders.

These cells can only be detected using microscopic inspection.

The HemoScreen™ analysis method, very similar to the gold -standard blood-smear, can accurately enumerate different abnormal cells at the primary care level, even before patients are symptomatic.

Early Heart Failure Diagnosis

Heart failure occurs when blood flow decreases or stops to a part of the heart, causing damage to the heart muscle. To adequately assess the risk of a given heart failure patient, there is a need for a combined-marker approach.

The “Early Heart Failure” HemoScreen™ diagnostic technology utilizes a unique combination of multiple pathophysiological pathway markers to provide immediate information on the patient’s risk status upon heart failure, at the point-of-care.